Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Verve Therapeutics, a clinical-stage biotechnology company focused on genetic medicines for cardiovascular disease, has granted 5,330 restricted stock units (RSUs) to a new employee under its 2024 Inducement Stock Incentive Plan. The grant, made on November 29, 2024, complies with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in equal annual installments over four years starting January 1, 2025, contingent on continued employment.
Verve Therapeutics, un'azienda biotecnologica in fase clinica focalizzata su medicine genetiche per le malattie cardiovascolari, ha concesso 5.330 unità azionarie riservate (RSU) a un nuovo dipendente nell'ambito del suo Piano di Incentivazione Azionaria per Induzione 2024. La concessione, effettuata il 29 novembre 2024, è conforme alla Regola di Quotazione Nasdaq 5635(c)(4). Le RSU matureranno in rate annuali uguali nel corso di quattro anni a partire dal 1 gennaio 2025, a condizione di un impiego continuativo.
Verve Therapeutics, una empresa biotecnológica en etapa clínica centrada en medicamentos genéticos para enfermedades cardiovasculares, ha otorgado 5.330 unidades de acciones restringidas (RSU) a un nuevo empleado bajo su Plan de Incentivos de Acciones por Inducción 2024. La concesión, realizada el 29 de noviembre de 2024, cumple con la Regla de Cotización de Nasdaq 5635(c)(4). Las RSU se acumularán en cuotas anuales iguales durante cuatro años a partir del 1 de enero de 2025, sujeto a la continuidad del empleo.
Verve Therapeutics, 심혈관 질환을 위한 유전자 치료제에 중점을 둔 임상 개발 단계의 생명공학 회사는 5,330개의 제한된 주식 단위(RSU)를 새로운 직원에게 2024 유도 주식 인센티브 계획에 따라 부여했습니다. 이 부여는 2024년 11월 29일에 이루어졌으며, 나스닥 상장 규칙 5635(c)(4)에 맞춰 진행되었습니다. RSU는 2025년 1월 1일부터 시작하여 4년 동안 매년 동일한 금액으로 분할되어 지급되며, 지속적인 고용을 조건으로 합니다.
Verve Therapeutics, une entreprise biopharmaceutique en phase clinique spécialisée dans les médicaments génétiques pour les maladies cardiovasculaires, a accordé 5.330 unités d'actions restreintes (RSU) à un nouvel employé dans le cadre de son Plan d'Incentive de Stocks pour Induction 2024. L'octroi, effectué le 29 novembre 2024, est conforme à la Règle de Cotation Nasdaq 5635(c)(4). Les RSU seront acquises par versements annuels égaux sur une période de quatre ans à compter du 1er janvier 2025, sous réserve d'une continuité d'emploi.
Verve Therapeutics, ein biopharmazeutisches Unternehmen in der klinischen Phase mit Fokus auf genetische Therapien für Herz-Kreislauf-Erkrankungen, hat 5.330 beschränkte Aktieneinheiten (RSUs) an einen neuen Mitarbeiter im Rahmen seines Induktions-Aktienanreizplans 2024 gewährt. Die Gewährung, die am 29. November 2024 stattfand, entspricht der Nasdaq-Listing-Regel 5635(c)(4). Die RSUs werden über einen Zeitraum von vier Jahren ab dem 1. Januar 2025 in gleichen jährlichen Raten fällig, vorbehaltlich einer kontinuierlichen Beschäftigung.
- None.
- None.
BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29, 2024, the company granted equity awards to one new employee, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to such new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
The employee received an aggregate of 5,330 restricted stock units (RSUs). The RSUs will vest in equal annual installments on the first four anniversaries of January 1, 2025, subject to such employee’s continued service with the company on each such vesting date.
About Verve Therapeutics
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic management to single-course gene editing medicines. The company’s lead programs – VERVE-101, VERVE-102, and VERVE-201 – target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established ASCVD who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia (HoFH). For more information, please visit www.VerveTx.com.
Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com
Media Contact
Ashlea Kosikowski
1AB
ashlea@1abmedia.com
FAQ
How many RSUs did Verve Therapeutics (VERV) grant to new employees on November 29, 2024?
What is the vesting schedule for Verve Therapeutics (VERV) RSUs granted in November 2024?
Under which plan did Verve Therapeutics (VERV) issue its November 2024 inducement grants?
